Epidermal growth factor receptor (EGFR) mutations are the second most common oncogenic
driver event in non-small cell lung cancer (NSCLC). Classical activating mutations (exon 19 …

Inframe insertions of three or more base pairs in exon 20 of the epidermal growth factor
receptor (EGFR) gene were among the first EGFR mutations to be identified as oncogenic …

Abstract Each year, about 5–6 cases out of 100,000 people are diagnosed with primary
malignant brain tumors, of which about 80% are malignant gliomas (MGs). Glioblastoma …

Lung adenocarcinoma, the most common subtype of non-small cell lung cancer, is
responsible for more than 500,000 deaths per year worldwide. Here, we report exome and …

Endocytosis entails selective packaging of cell-surface proteins, such as receptors for
cytokines and adhesion components, in cytoplasmic vesicles (endosomes). The series of …

The epidermal growth factor receptor (EGFR) is a receptor tyrosine kinase that plays a
critical role in the pathogenesis of many cancers. The structure of intact forms of this receptor …

The epidermal growth factor receptor (EGFR) plays vital roles in cellular processes including
cell proliferation, survival, motility, and differentiation. The dysregulated activation of the …

In contrast to the active conformations of protein kinases, which are essentially the same for
all kinases, inactive kinase conformations are structurally diverse. Some inactive …

Our current understanding of epidermal growth factor receptor (EGFR) autoinhibition is
based on X-ray structural data of monomer and dimer receptor fragments and does not …

The∼ 230-residue C-terminal tail of the epidermal growth factor receptor (EGFR) is
phosphorylated upon activation. We examined whether this phosphorylation is affected by …